Izenivetmab

❧

Wikipedia

Izenivetmab
Monoclonal antibody
TypeWhole antibody
TargetNerve growth factor (NGF)
Clinical data
Trade namesLenivia
Other namesZTS-00075623
Routes of
administration		Subcutaneous
ATCvet code
Legal status
Legal status
Identifiers
CAS Number
UNII
Chemical and physical data
FormulaC6570H10078N1750O2022S48
Molar mass147472.00 g·mol−1

Izenivetmab, sold under the brand name Lenivia, is a canine monoclonal antibody medication used for the alleviation of pain associated with osteoarthritis in dogs.[2]

Izenivetmab was authorized for veterinary use in Canada in October 2025,[3] and in the European Union in November 2025.[4]

Medical uses

Izenivetmab is indicated for the alleviation of pain associated with osteoarthritis in dogs.[5]

Society and culture

Izenivetmab was authorized for veterinary use in Canada in October 2025,[3] and in the European Union in November 2025.[4]

Names

Izenivetmab is the international nonproprietary name.[6]

Izenivetmab is sold under the brand name Lenivia.[3][4]

References

  1. ↑ "Lenivia EPAR". European Medicines Agency (EMA). 10 October 2025. Retrieved 22 December 2025.
  2. ↑ "Meeting highlights from the Committee for Veterinary Medicinal Products (CVMP) 7-9 October 2025". European Medicines Agency (EMA). 10 October 2025. Retrieved 22 December 2025. Text was copied from this source which is copyright European Medicines Agency. Reproduction is authorized provided the source is acknowledged.
  3. 1 2 3 "Zoetis Announces Health Canada Approval of Lenivia (izenivetmab injection) for Alleviation of Osteoarthritis (OA) Pain in Dogs" (Press release). Zoetis. 15 October 2025. Retrieved 22 December 2025.
  4. 1 2 3 "Zoetis Receives European Commission Marketing Authorization for Lenivia (izenivetmab) to Reduce Pain Associated with Osteoarthritis (OA) in Dogs" (Press release). Zoetis. 26 November 2025. Retrieved 22 December 2025.
  5. ↑ "Lenivia 0.5 mg". European Medicines Agency (EMA). 20 November 2025. Retrieved 22 December 2025.
  6. ↑ World Health Organization (2022). "International nonproprietary names for pharmaceutical substances (INN): recommended INN: list 88". WHO Drug Information. 36 (3). hdl:10665/363551.